HIV infection
Conditions
Interventions
Starting from December 2017 to the end of December 2020, we will conduct at least one malignant tumor screening tests, including FDG-PET/CT and blood tumor marker test.
Sponsors
National Hospital Organization Nagoya Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) HIV infected patients with hemophilia who are 35 years old or older or 2) HIV litigation plaintiffs resident in Tokai block and 3) Consent to participant has been obtained in a written form.
Exclusion criteria
Exclusion criteria: 1) If an attending physician decides the patient requires urgent treatment 2)A patient with poor control of diabetes (FBS>150mg/dL) 3) A patient with serious underlying disease, which may lead to liver/kidney dysfunction and/or metabolic disorder 4) A patient with mental illness or psychiatric symptoms determined to confront difficulty when participating in the study 5)A patient with history of hypersensitivity to FDG 6) Other patients, whose attending physician has determined inappropriate to participant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of undiagnosed malignant tumor in HIV positive patients with hemophilia | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Yokomaku
National Hospital Organization Nagoya Medical Center Department of AIDS clinic
Outcome results
None listed